Overview

PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First Line Chemotherapy

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of PD-1 immune checkpoint inhibitor combined with bevacizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

XIANG YANQUN

Treatments:

Bevacizumab
Immune Checkpoint Inhibitors